Back to top
more

AC Immune (ACIU)

(Delayed Data from NSDQ)

$4.05 USD

4.05
206,978

+0.14 (3.58%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $4.06 +0.01 (0.25%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

by Zacks Equity Research

Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.

AC Immune (ACIU) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in AC Immune SA (ACIU).

Top Ranked Momentum Stocks to Buy for November 21st

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st:

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 30.77% and 36.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 13.04% and 5.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

    by Zacks Equity Research

    On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

      What's in the Cards for Inovio (INO) This Earnings Season?

      by Zacks Equity Research

      During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.

        Moving Average Crossover Alert: AC Immune SA (ACIU)

        by Zacks Equity Research

        AC Immune SA (ACIU) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

          Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session

          by Zacks Equity Research

          Fortress Biotech, Inc. (FBIO) shares rose over 5% in the last trading session.